Merck

Merck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.

Merck

Merck announced that the company will lay off 170 people from Cambridge, Massachusetts-based Acceleron Pharma, which was acquired during November 2021 for about $11.5 billion.

The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Merck announced that the company’s proposed treatment Keytruda for non-small cell lung cancer delivered positive results from a Phase III trial. 

The U.S. Food and Drug Administration placed a partial clinical hold on Alpine Immune Sciences’ NEON-2 trial, which is evaluating davoceticept (ALPN-202) in combination with Merck’s immunotherapy pembrolizumab (Keytruda) in adults with cancer.

Keytruda

Merck announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant Keytruda in combination with chemotherapy followed by adjuvant Keytruda as monotherapy, significantly prolonged event-free survival compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).

Merck

Researchers studying Merck & Co. Inc.’s cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing area of study for treatment of chronic HIV infection.

The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. Additionally, the FDA expanded the indication for Keytruda as adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).

The U.S. Food and Drug Administration approved Merck’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) for adjuvant treatment of renal cell carcinoma (RCC) patients at intermediate-high or high risk of recurrence after nephrectomy or following nephrectomy and resection of metastatic lesions.

Merck

Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.